Literature DB >> 11823687

Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival.

Ly V Do1, Tri M Do, Robert Smith, Robert G Parker.   

Abstract

The role of postoperative irradiation in patients with clinically localized prostate cancer, either as an adjuvant or salvage radiotherapy, remains controversial. In this study, we evaluate the impact of postoperative radiotherapy on patients diagnosed with prostate cancer with respect to biochemical and clinical disease free survival. Between 1987 and 1996, 179 patients with clinically localized prostate cancer were found to have adverse histopathologic findings on radical prostatectomy specimens (positive surgical margins, extracapsular extension, and seminal vesicle invasion). Of these patients, 42 were referred for postoperative adjuvant radiotherapy, whereas 73 were referred for salvage irradiation because of rising serum prostate-specific antigen (PSA) levels postoperatively. The remaining 64 patients underwent prostatectomy only. The 10-year biochemical relapse-free survival (RFS) from date of surgery were 88%, 45%, and 25% for patients treated with postoperative adjuvant radiotherapy, salvage irradiation, and with surgery alone, respectively (p = 0.046). Ten-year distant RFS from date of surgery were 82%, 74%, and 44% for adjuvantly treated patients, those with salvage radiotherapy, and those with surgery alone, respectively (p = 0.0180). Ten-year overall disease RFS from date of surgery was 89%, 76%, and 30% for adjuvantly treated patients, those with salvage radiotherapy, and those with surgery alone, respectively (p = 0.0237). Multivariate analyses revealed that a preoperative PSA greater than 20 ng/ml and pathologic Gleason Score of 8 to 10 were adverse predictors for biochemical relapse, whereas pathologic Gleason Score of 8 to 10, seminal vesicle invasion, and extracapsular extension were adverse predictors of distant metastases. Postoperative radiotherapy, either delivered as adjuvant treatment for adverse histopathologic findings or as salvage therapy for local relapses, appear to confer superior local, distant disease RFS, and overall disease RFS than surgery alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823687     DOI: 10.1097/00000421-200202000-00001

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

Review 1.  [pT3R1 prostate cancer : Immediate or delayed radiotherapy after radical prostatectomy?].

Authors:  D Bottke; T Wiegel
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

2.  Postoperative radiotherapy after radical prostatectomy: indications and open questions.

Authors:  Pirus Ghadjar; Daniel Zwahlen; Daniel M Aebersold; F Zimmermann
Journal:  Prostate Cancer       Date:  2012-02-28

Review 3.  Adjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis.

Authors:  Changhao Chen; Tianxin Lin; Yu Zhou; Doudou Li; Kewei Xu; Zhihua Li; Xinxiang Fan; Guangzheng Zhong; Wang He; Xu Chen; Xianyin He; Jian Huang
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

4.  The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis.

Authors:  Ronggui Tao; Jindong Dai; Yunjin Bai; Jiyu Yang; Guangxi Sun; Xingming Zhang; Jinge Zhao; Hao Zeng; Pengfei Shen
Journal:  Radiat Oncol       Date:  2019-11-09       Impact factor: 3.481

5.  Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience.

Authors:  Laurent Quero; Pierre Mongiat-Artus; Vincent Ravery; Claude Maylin; François Desgrandchamps; Christophe Hennequin
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

Review 6.  Long-term oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer: Systemic review and meta-analysis of 5-year and 10-year follow-up data.

Authors:  Ja Yoon Ku; Chan Ho Lee; Hong Koo Ha
Journal:  Korean J Urol       Date:  2015-11-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.